Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor: Ligand pathway in T cells

Journal of Immunology

Volumn 166, Issue 4, 2001, Pages 2364-2371

  Prager, E ^a   Staffler, G ^a   Majdic, O ^a   Saemann M D ^a   Godar S ^a   Zlabinger, G J ^a   Stockinger, H ^a  

^a Vienna International Research Cooperation Center   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0035865251     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.4.2364     Document Type: Article

References (64)

1. A two-step, two-signal model for the primary activation of precursor helper T cells
2. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
3. Negative regulation of T cell activation
4. Fas and the art of lymphocyte maintenance
5. Pathways leading to cell death in T cells
6. TRAIL: A molecule with multiple receptors and control mechanisms
7. Is CTLA-4 a master switch for peripheral T cell tolerance?
8. The emerging role of CTLA-4 as an immune attenuator
9. CTLA-4 and T cell activation
10. NK cell receptors
11. Natural killer cell receptors
12. Regulation of KIR expression in human T cells: A safety mechanism that may impair protective T-cell responses
13. Interaction of CD31 with a heterophilic counterreceptor involved in downregulation of human T cell responses
14. The biology of PECAM-1
15. Migration of leukocytes across endothelium and beyond: Molecules involved in the transmigration and fate of monocytes
16. A heterophilic adhesion mechanism for platelet/endothelial cell adhesion molecule 1 (CD31)
17. Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans
18. 3 integrin involved in adhesion of leukocytes to endothelium
19. 3 as a heterotypic ligand for CD31/PECAM-1
20. PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes
21. Human CD38 (ADP-ribosyl cyclase) is a counterreceptor of CD31, an Ig superfamily member
22. Soluble domain I of plateletendothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo
23. Genetic evidence for functional redundancy of platelet-endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions
24. Transgenic mice expressing different levels of soluble platelet/endothelial cell adhesion molecule-IgG display distinct inflammatory phenotypes
25. Involvement of endothelial PECAM-1/CD31 in angiogenesis
26. Molecular characterization and functional analysis of the leukocyte surface protein CD31
27. Co-ligation of CD31 and FcyRII induces cytokine production in human monocytes
28. Ligation of CD3I/PECAM-1 modulates the function of lymphocytes, monocytes and neutrophils
29. CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes
30. T cell interaction with ICAM-1-deficient endothelium in vitro: Essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells
31. Phenotype of human T cells expressing CD31, a molecule of the immunoglobulin supergene family
32. CD31 (PECAM-1 is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells
33. CD31, a novel cell surface marker for CD4 cells of suppressor lineage, unaltered by state of activation
34. Switched at birth: A new family for PECAM-1
35. Involvement of CD31 in lymphocyte-mediated immune responses: Importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide
36. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease
37. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus
38. Human major group rhinoviruses downmodulate the accessory function of monocytes by inducing IL-10
39. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
40. - T cells
41. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor
42. Models of T cell anergy: Is there a common molecular mechanism?
43. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
44. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
45. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
46. CTLA-4 regulates tolerance induction and T cell differentiation in vivo
47. FcR-mediated inhibition of cell activation and other forms of coinhibition
48. Regulation of immune responses through inhibitory receptors
49. Positive versus negative signaling by lymphocyte antigen receptors
50. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
51. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells
52. + T cells
53. Paradoxical inhibition of T cell function in response to CTLA-4 blockade; Heterogeneity within the human T cell population
54. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
55. + T cells
56. Induction of T cell anergy in the absence of CTLA-4/B7 interaction
57. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
58. + regulatory cells that control intestinal inflammation
59. + T-cell subsets in autoimmunity
60. Homeostatic mechanisms in the control of autoimmunity
61. Control of immune pathology by regulatory T cells
62. TGF-β: A balancing act
63. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
64. + T cells: A population of T cells with immune regulatory activities in vitro